Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

NOVOLOG PENFILL 100 UNIT/ML

insulin aspart
$8.5732per ML

Strength

100 [iU]/mL

Manufacturer

Novo Nordisk

NDC

00169330312

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

INTRAVENOUS; SUBCUTANEOUS

Last Updated

4/22/2026

Active Ingredients

INSULIN ASPART

Approval Type

Biologic (BLA)

FDA Application

BLA020986

On Market Since

8/27/2001

Pharmacological Classes

Insulin Analog
Insulin

Price History

1W

0.0%

1M

+0.0%

3M

+0.0%

6M

-0.0%

1Y

-0.1%

3Y

-75.0%

5Y

-75.1%

All

-53.6%

Generic Alternatives

Save up to 19%

1 alternative • Same active ingredient

NOVOLOG MIX 70-30 VIAL
Brand
00169368512•Novo Nordisk
$6.9325
Save 19%

Related Drugs

Same classification

HUMULIN 70-30 VIAL
Brand
00002871501•Eli Lilly and Company
$4.2626
per ML
HUMULIN R 100 UNIT/ML VIAL
Brand
00002821501•Eli Lilly and Company
$4.2660
per ML
HUMULIN N 100 UNIT/ML VIAL
Brand
00002831501•Eli Lilly and Company
$4.2686
per ML
NOVOLIN R 100 UNIT/ML VIAL
Brand
00169183311•Novo Nordisk
$4.6226
per ML
NOVOLIN N 100 UNIT/ML VIAL
Brand
00169183411•Novo Nordisk
$4.6249
per ML
NOVOLIN 70-30 100 UNIT/ML VIAL
Brand
00169183711•Novo Nordisk
$4.6290
per ML
AFREZZA (REGULAR INSULIN) 4 UNIT CARTRIDGE
Brand
47918087490•Mannkind Corporation
$5.1957
per EA
NOVOLIN R 100 UNIT/ML FLEXPEN
Brand
00169300315•Novo Nordisk
$5.8194
per ML
NOVOLIN 70-30 FLEXPEN
Brand
00169300715•Novo Nordisk
$5.8261
per ML
NOVOLIN N 100 UNIT/ML FLEXPEN
Brand
00169300415•Novo Nordisk
$5.8268
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy